About the Company


Prof. Marek Jutel

"ALL-MED" Specjalistyczna Opieka Medyczna. Medyczny Instytut Badawczy (Medical Specialist Care. Medical Research Institute ) was established by prof. Marek Jutel in 2006 as a center of allergy and asthma treatment, allergen-specific immunotherapy (AIT) as well as research and development (R&D) company focused on new methods of diagnosis and treatment of allergies and other immune-mediated diseases. "ALL-MED" has been recognized by the European ommission as SME (small and medium size enterprice) in the R&D sector, which receives EU support for its innovative activity. Since its inception, the out-patient clinic has a contract with the open state insurance - National Health Fund and takes care of patients with all types of allergies. ALL-MED is also a well-known and esteemed clinical trial centre. Novel methods of allergen immunotherapy (AIT) i.e. allergen desensitization as well as pharmacological and immunological therapies, so-called biological therapies in the treatment of asthma, chronic obstructive pulmonary disease and autoimmune diseases are investigated.

"ALL-MED" Medical Research Institute is a full memeber of an international research consortium, which includes the University Clinical Center in Amsterdam (AMC), University Hospital of Odense (Denmark), University Hospital of Heidelberg, University of Salzburg and Biomay (Austria). The aim of the consortium is the development and implementation of novel allergy vaccines and enjoys financial support from the Europen Union 7th Framework Programme.

"ALL-MED" has the most modern clinical facilities including Environmental Exposure Chamber (EEC), as one of the very few centers in Europe . In addition the diagnostic and research part has most modern equipment for immunologic tests, which include: multicolour flow cytometry (FACSCanto II, Beckman Coulter EPICS XL-MCL), real-time PCR (Applied Biosystems ABI Prism 7900HT ), systems to assess the concentration of more than 100 proteins in a single sample (BioRad Bioplex 200), systems for cell separation (Miltenyi AutoMACS separator), advanced confocal microscopy (Leitz Ergolux), systems for culturing of various immunocompetent or structural cell types, genetic research tools, and many others. These methods allow to assess a wide range of immunological parameters for basic and translational research, as well as for clinical application within the clinical trials. These markers are subject of validation and show potential of future application in routine diagnosis and monitoring of therapy as biomarkers.

Prof. Marek Jutel (http://pl.wikipedia.org/wiki/Marek_Jutel) belongs to the leading Polish allergists of an international out-reach. He served as the chair of the Scientific Programme Committee of the European Academy of Allergy and Clinical Immunology (http://eaaci.net/) and recently has been nominated as vice-President – Treasurer by the EAACI Executive Committee. Prof. Marek Jutel is the author of over 200 scientific publications. He published in the most prestigious scientific journals including Nature, Nature Medicine, PNAS, Journal of Allergy and Clinical Immunology. He pioneered in research with recombinant allergen vaccines. Prof. Marek Jutel is regularly invited speaker during the key medical conferences in the field of allergy, clinical immunology, internal medicine and related specialties (http://all-med.wroclaw.pl/z-zycia-all-medu).